頭頸部扁平上皮がんの世界市場レポート 2025年

頭頸部扁平上皮がん市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.2％で28億1,000万米ドルに成長します。予測期間中に予想される成長は、タバコ消費量の増加、高齢者人口の増加、有利な政府政策、がん罹患率の増加、アルコール消費量の増加などの要因によってもたらされます。この期間の主な動向としては、標的療法の採用、研究投資の増加、免疫療法の統合、技術の進歩、薬剤製剤の改良などが挙げられます。

タバコとアルコールの消費量の増加は、頭頸部扁平上皮がん市場の拡大を促進すると予想されます。この増加は、文化的規範、社会的圧力、ストレス、マーケティング、これらの物質の容易な入手といった要因に影響されています。タバコやアルコールの摂取は、粘膜に慢性的な刺激や損傷を与え、遺伝子変異を誘発し、免疫反応を弱めることにより、頭頸部扁平上皮がん（HNSCC）のリスク上昇に寄与し、これらすべてが頭頸部領域でのがん開発を促進します。例えば、2024年9月、米国疾病予防管理センター（CDC）は、タバコの使用は依然として米国で予防可能な疾病と死亡の主な原因であると報告しました。2022年には、人口の19.8％にあたる約4,920万人の成人がタバコ製品を使用していました。さらに、英国の国民保健サービスが2024年6月に発表したデータによると、成人の81％が前年にアルコールを摂取しており、男性の84％、女性の78％がこの期間にアルコールを使用したと報告しています。このように、タバコとアルコールの使用増加が頭頸部扁平上皮がん市場の成長に寄与しています。

がん治療のイノベーションを促進するため、頭頸部扁平上皮がん分野の主要企業は戦略的パートナーシップを結んでいます。このような提携により、企業はリソースや専門知識を共有し、研究開発を加速させ、イノベーションを後押しすることができます。このようなパートナーシップは、力を合わせることによって、より迅速な商業化をも促進し、企業がより広い市場に参入し、新たな患者集団にアクセスするのを助ける。例えば、2024年10月、米国のバイオテクノロジー企業であるExelixis Inc.はMerck &Co.Inc.と提携しました。この提携は、ザンザリンチニブとKEYTRUDAおよびWELIREGとの併用療法を検討することを目的としており、HNSCCおよび腎細胞がん（RCC）患者の治療成績向上を目標としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界頭頸部扁平上皮がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の頭頸部扁平上皮がん市場：成長率分析
• 世界の頭頸部扁平上皮がん市場の実績：規模と成長, 2019-2024
• 世界の頭頸部扁平上皮がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界頭頸部扁平上皮がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の頭頸部扁平上皮がん市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 唾液腺
• 口腔および咽頭
• 鼻腔と副鼻腔
• 鼻咽頭
• 喉頭
• 下咽頭
• 世界の頭頸部扁平上皮がん市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮成長因子受容体（EGFR）阻害剤
• 免疫チェックポイント阻害剤
• その他の薬物クラス
• 世界の頭頸部扁平上皮がん市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• オーラル
• その他の投与経路
• 世界の頭頸部扁平上皮がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• 化学療法
• 免疫療法
• 世界の頭頸部扁平上皮がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• 世界の頭頸部扁平上皮がん市場唾液腺の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大唾液腺（耳下腺、顎下腺）
• 小唾液腺
• 世界の頭頸部扁平上皮がん市場口腔および口腔咽頭のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 口腔がん
• 口腔咽頭がん（扁桃腺、舌根部）
• 世界の頭頸部扁平上皮がん市場鼻腔と副鼻腔の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鼻腔がん
• 副鼻腔がん
• 世界の頭頸部扁平上皮がん市場、鼻咽頭のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鼻咽頭がん
• 世界の頭頸部扁平上皮がん市場喉頭のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喉頭上がん
• 声門喉頭がん
• 声門下喉頭がん
• 世界の頭頸部扁平上皮がん市場、下咽頭のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下咽頭がん

第7章 地域別・国別分析

• 世界の頭頸部扁平上皮がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の頭頸部扁平上皮がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 頭頸部扁平上皮がん市場：競合情勢
• 頭頸部扁平上皮がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Rakuten Medical Inc.
• Exelixis Inc.
• Akeso Inc.
• Fortress Biotech Inc.
• Hookipa Pharma Inc.
• MacroGenics Inc.
• Theriva Biologics Inc.
• Turnstone Biologics Inc.
• Nykode Therapeutics AS

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 頭頸部扁平上皮がん市場2029：新たな機会を提供する国
• 頭頸部扁平上皮がん市場2029：新たな機会を提供するセグメント
• 頭頸部扁平上皮がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Head and neck squamous cell carcinoma (HNSCC) is a malignant tumor that arises in the squamous epithelium of the upper aerodigestive tract, affecting areas such as the oral cavity, pharynx, and larynx. It is one of the most common types of head and neck cancer, often associated with risk factors such as tobacco use, alcohol consumption, and infections such as human papillomavirus (HPV).

The main types of head and neck squamous cell carcinoma include salivary gland, oral and oropharyngeal, nasal cavity and paranasal sinuses, nasopharyngeal, laryngeal, and hypopharyngeal cancers. Salivary gland cancers are rare malignancies that develop in the glands producing saliva and are usually treated with surgery, radiation, and targeted therapies. Drug classes used in treatment include epidermal growth factor receptor (EGFR) inhibitors, immune checkpoint inhibitors, and other therapies. These can be administered via intravenous, oral, or other routes. Treatment methods include radiation therapy, chemotherapy, and immunotherapy, with administration across various settings such as hospitals, specialty clinics, and ambulatory surgical centers.

The head and neck squamous cell carcinoma market research report is one of a series of new reports from The Business Research Company that provides head and neck squamous cell carcinoma market statistics, including the head and neck squamous cell carcinoma industry global market size, regional shares, competitors with the head and neck squamous cell carcinoma market share, detailed head and neck squamous cell carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the head and neck squamous cell carcinoma industry. This head and neck squamous cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The head and neck squamous cell carcinoma market size has grown strongly in recent years. It will grow from $1.81 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to increased awareness and screening, the growth of combination therapies, the development of healthcare infrastructure, rising healthcare spending, and the increasing incidence of head and neck squamous cell carcinoma.

The head and neck squamous cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The expected growth in the forecast period is driven by factors such as rising tobacco consumption, a growing geriatric population, favorable government policies, an increasing incidence of cancer, and higher alcohol consumption. Key trends during this period include the adoption of targeted therapies, increased investment in research, the integration of immunotherapy, technological advancements, and improvements in drug formulation.

The growing consumption of tobacco and alcohol is anticipated to drive the expansion of the head and neck squamous cell carcinoma market. This rise is influenced by factors such as cultural norms, social pressures, stress, marketing, and the easy availability of these substances. The consumption of tobacco and alcohol contributes to an increased risk of head and neck squamous cell carcinoma (HNSCC) by causing chronic irritation and damage to the mucosal lining, triggering genetic mutations, and weakening immune responses, all of which promote cancer development in the head and neck area. For example, in September 2024, the Centers for Disease Control and Prevention (CDC) reported that tobacco use remains the leading cause of preventable disease and death in the U.S. In 2022, approximately 49.2 million adults, or 19.8% of the population, used tobacco products. Additionally, data released by the UK's National Health Service in June 2024 indicated that 81% of adults consumed alcohol in the previous year, with 84% of men and 78% of women reporting alcohol use during this period. As such, the increasing use of tobacco and alcohol is contributing to the growth of the head and neck squamous cell carcinoma market.

To foster innovation in cancer treatments, leading companies in the head and neck squamous cell carcinoma field are forming strategic partnerships. These collaborations allow companies to pool resources and expertise, speeding up research and development while boosting innovation. By joining forces, these partnerships also facilitate faster commercialization, helping companies reach broader markets and access new patient groups. For example, in October 2024, Exelixis Inc., a U.S.-based biotech firm, teamed up with Merck & Co. Inc., a U.S.-based pharmaceutical company, to further cancer treatments. This collaboration aims to explore the combination of zanzalintinib with KEYTRUDA and WELIREG, targeting enhanced outcomes for patients with HNSCC and renal cell carcinoma (RCC).

In March 2023, Flamingo Therapeutics NV, a Belgian biotechnology firm, merged with Dynacure SAS in a deal with undisclosed terms. This merger allows the two companies to combine their expertise in RNA-targeting and clinical drug development, creating a prominent oncology entity focused on advancing cutting-edge therapies. This includes Flamingo's danvatirsen program, currently undergoing Phase II trials for head and neck cancer, and the FTX-001 program targeting MALAT-1 in solid tumors. Dynacure SAS is a Belgium-based biotech company specializing in developing therapies for patients with rare and severe orphan diseases.

Major players in the head and neck squamous cell carcinoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Rakuten Medical Inc., Exelixis Inc., Akeso Inc., Fortress Biotech Inc., Hookipa Pharma Inc., MacroGenics Inc., Theriva Biologics Inc., Turnstone Biologics Inc., Nykode Therapeutics AS, Immutep Limited, Tizona Therapeutics Inc., Checkpoint Therapeutics Inc., and Zenith Epigenetics Ltd.

North America was the largest region in the head and neck squamous cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in head and neck squamous cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the head and neck squamous cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The head and neck squamous cell carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, rehabilitation services, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The head and neck squamous cell carcinoma market also includes sales of therapeutics, regenerative products, targeted therapy treatments, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Head And Neck Squamous Cell Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on head and neck squamous cell carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for head and neck squamous cell carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The head and neck squamous cell carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Salivary Gland; Oral And Oropharyngeal; Nasal Cavity And Paranasal Sinuses; Nasopharyngeal; Laryngeal; Hypopharyngeal
• 2) By Drug Class: Epidermal Growth Factor Receptor (Egfr) Inhibitors; Immune Checkpoint Inhibitors; Other Drug Class
• 3) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
• 4) By Treatment: Radiation Therapy; Chemotherapy; Immunotherapy
• 5) By End-user: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Salivary Gland: Major Salivary Glands (Parotid, Submandibular); Minor Salivary Glands
• 2) By Oral And Oropharyngeal: Oral Cavity Cancer; Oropharyngeal Cancer (Tonsils, Base Of Tongue)
• 3) By Nasal Cavity And Paranasal Sinuses: Nasal Cavity Cancer; Paranasal Sinus Cancer
• 4) By Nasopharyngeal: Nasopharyngeal Carcinoma
• 5) By Laryngeal: Supraglottic Laryngeal Cancer; Glottic Laryngeal Cancer; Subglottic Laryngeal Cancer
• 6) By Hypopharyngeal: Hypopharyngeal Cancer
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Bayer AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Head And Neck Squamous Cell Carcinoma Market Characteristics

3. Head And Neck Squamous Cell Carcinoma Market Trends And Strategies

4. Head And Neck Squamous Cell Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Head And Neck Squamous Cell Carcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Head And Neck Squamous Cell Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Head And Neck Squamous Cell Carcinoma Market Growth Rate Analysis
• 5.4. Global Head And Neck Squamous Cell Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Head And Neck Squamous Cell Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Head And Neck Squamous Cell Carcinoma Total Addressable Market (TAM)

6. Head And Neck Squamous Cell Carcinoma Market Segmentation

• 6.1. Global Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salivary Gland
• Oral And Oropharyngeal
• Nasal Cavity And Paranasal Sinuses
• Nasopharyngeal
• Laryngeal
• Hypopharyngeal
• 6.2. Global Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epidermal Growth Factor Receptor (Egfr) Inhibitors
• Immune Checkpoint Inhibitors
• Other Drug Class
• 6.3. Global Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Oral
• Other Route Of Administration
• 6.4. Global Head And Neck Squamous Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• 6.5. Global Head And Neck Squamous Cell Carcinoma Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• 6.6. Global Head And Neck Squamous Cell Carcinoma Market, Sub-Segmentation Of Salivary Gland, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Major Salivary Glands (Parotid, Submandibular)
• Minor Salivary Glands
• 6.7. Global Head And Neck Squamous Cell Carcinoma Market, Sub-Segmentation Of Oral And Oropharyngeal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Cavity Cancer
• Oropharyngeal Cancer (Tonsils, Base Of Tongue)
• 6.8. Global Head And Neck Squamous Cell Carcinoma Market, Sub-Segmentation Of Nasal Cavity And Paranasal Sinuses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nasal Cavity Cancer
• Paranasal Sinus Cancer
• 6.9. Global Head And Neck Squamous Cell Carcinoma Market, Sub-Segmentation Of Nasopharyngeal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nasopharyngeal Carcinoma
• 6.10. Global Head And Neck Squamous Cell Carcinoma Market, Sub-Segmentation Of Laryngeal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supraglottic Laryngeal Cancer
• Glottic Laryngeal Cancer
• Subglottic Laryngeal Cancer
• 6.11. Global Head And Neck Squamous Cell Carcinoma Market, Sub-Segmentation Of Hypopharyngeal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypopharyngeal Cancer

7. Head And Neck Squamous Cell Carcinoma Market Regional And Country Analysis

• 7.1. Global Head And Neck Squamous Cell Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Head And Neck Squamous Cell Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Head And Neck Squamous Cell Carcinoma Market

• 8.1. Asia-Pacific Head And Neck Squamous Cell Carcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Head And Neck Squamous Cell Carcinoma Market

• 9.1. China Head And Neck Squamous Cell Carcinoma Market Overview
• 9.2. China Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Head And Neck Squamous Cell Carcinoma Market

• 10.1. India Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Head And Neck Squamous Cell Carcinoma Market

• 11.1. Japan Head And Neck Squamous Cell Carcinoma Market Overview
• 11.2. Japan Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Head And Neck Squamous Cell Carcinoma Market

• 12.1. Australia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Head And Neck Squamous Cell Carcinoma Market

• 13.1. Indonesia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Head And Neck Squamous Cell Carcinoma Market

• 14.1. South Korea Head And Neck Squamous Cell Carcinoma Market Overview
• 14.2. South Korea Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Head And Neck Squamous Cell Carcinoma Market

• 15.1. Western Europe Head And Neck Squamous Cell Carcinoma Market Overview
• 15.2. Western Europe Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Head And Neck Squamous Cell Carcinoma Market

• 16.1. UK Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Head And Neck Squamous Cell Carcinoma Market

• 17.1. Germany Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Head And Neck Squamous Cell Carcinoma Market

• 18.1. France Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Head And Neck Squamous Cell Carcinoma Market

• 19.1. Italy Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Head And Neck Squamous Cell Carcinoma Market

• 20.1. Spain Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Head And Neck Squamous Cell Carcinoma Market

• 21.1. Eastern Europe Head And Neck Squamous Cell Carcinoma Market Overview
• 21.2. Eastern Europe Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Head And Neck Squamous Cell Carcinoma Market

• 22.1. Russia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Head And Neck Squamous Cell Carcinoma Market

• 23.1. North America Head And Neck Squamous Cell Carcinoma Market Overview
• 23.2. North America Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Head And Neck Squamous Cell Carcinoma Market

• 24.1. USA Head And Neck Squamous Cell Carcinoma Market Overview
• 24.2. USA Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Head And Neck Squamous Cell Carcinoma Market

• 25.1. Canada Head And Neck Squamous Cell Carcinoma Market Overview
• 25.2. Canada Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Head And Neck Squamous Cell Carcinoma Market

• 26.1. South America Head And Neck Squamous Cell Carcinoma Market Overview
• 26.2. South America Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Head And Neck Squamous Cell Carcinoma Market

• 27.1. Brazil Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Head And Neck Squamous Cell Carcinoma Market

• 28.1. Middle East Head And Neck Squamous Cell Carcinoma Market Overview
• 28.2. Middle East Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Head And Neck Squamous Cell Carcinoma Market

• 29.1. Africa Head And Neck Squamous Cell Carcinoma Market Overview
• 29.2. Africa Head And Neck Squamous Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Head And Neck Squamous Cell Carcinoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Head And Neck Squamous Cell Carcinoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Head And Neck Squamous Cell Carcinoma Market Competitive Landscape And Company Profiles

• 30.1. Head And Neck Squamous Cell Carcinoma Market Competitive Landscape
• 30.2. Head And Neck Squamous Cell Carcinoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Head And Neck Squamous Cell Carcinoma Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Novartis AG
• 31.4. GSK plc
• 31.5. Eli Lilly and Company
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Rakuten Medical Inc.
• 31.8. Exelixis Inc.
• 31.9. Akeso Inc.
• 31.10. Fortress Biotech Inc.
• 31.11. Hookipa Pharma Inc.
• 31.12. MacroGenics Inc.
• 31.13. Theriva Biologics Inc.
• 31.14. Turnstone Biologics Inc.
• 31.15. Nykode Therapeutics AS

32. Global Head And Neck Squamous Cell Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Head And Neck Squamous Cell Carcinoma Market

34. Recent Developments In The Head And Neck Squamous Cell Carcinoma Market

35. Head And Neck Squamous Cell Carcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Head And Neck Squamous Cell Carcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Head And Neck Squamous Cell Carcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Head And Neck Squamous Cell Carcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer